| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| KRYSKrystal Biotech, Inc. | 8.18B | 282.01 | 94.00 | 473.02% | 53.3% | 17.48% | 1.46% | 0.01 |
| BMRNBioMarin Pharmaceutical Inc. | 10.58B | 55.07 | 24.92 | 17.97% | 16.82% | 8.59% | 4.49% | 0.11 |
| SRPTSarepta Therapeutics, Inc. | 2.23B | 21.31 | 9.11 | 52.97% | -11.25% | -20.57% | 0.88 | |
| RAREUltragenyx Pharmaceutical Inc. | 2.27B | 23.50 | -3.74 | 29.01% | -91.95% | -35.88% | 0.15 | |
| DYNDyne Therapeutics, Inc. | 2.7B | 16.42 | -4.87 | -61.26% | 0.04 | |||
| TVTXTravere Therapeutics, Inc. | 2.54B | 28.40 | -6.96 | 60.55% | -20.32% | -120.36% | 6.80 | |
| BEAMBeam Therapeutics Inc. | 3.25B | 32.05 | -7.00 | -83.18% | -7.44% | -42.92% | 0.22 | |
| SLNOSoleno Therapeutics, Inc. | 2.25B | 41.95 | -9.58 | -79.5% | -15.85% | 0.22 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 8.12M | 4.61M | 1.53M | 10.58M | 13.38M | 6.95M | 7.78M | 51.17M | 266.72M | 363.64M |
| Revenue Growth % | -0.42% | -0.43% | -0.67% | 5.92% | 0.26% | -0.48% | 0.12% | 5.58% | 4.21% | 0.36% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 3.52M | 12.14M | 44.4M | 44.26M |
| COGS % of Revenue | - | - | - | - | - | - | 0.45% | 0.24% | 0.17% | 0.12% |
| Gross Profit | 8.12M | 4.61M | 1.53M | 10.58M | 13.38M | 6.95M | 4.25M | 39.04M | 222.32M | 319.38M |
| Gross Margin % | 1% | 1% | 1% | 1% | 1% | 1% | 0.55% | 0.76% | 0.83% | 0.88% |
| Gross Profit Growth % | -0.42% | -0.43% | -0.67% | 5.92% | 0.26% | -0.48% | -0.39% | 8.17% | 4.7% | 0.44% |
| Operating Expenses | 49.94M | 77.53M | 113.07M | 165.34M | 240.09M | 337.57M | 456.05M | 600.85M | 677.86M | 598.15M |
| OpEx % of Revenue | 6.15% | 16.83% | 73.9% | 15.63% | 17.95% | 48.55% | 58.63% | 11.74% | 2.54% | 1.64% |
| Selling, General & Admin | 9.41M | 11.5M | 13.48M | 25.06M | 48.47M | 76.67M | 160.18M | 215.85M | 258.79M | 284.55M |
| SG&A % of Revenue | 1.16% | 2.5% | 8.81% | 2.37% | 3.62% | 11.03% | 20.59% | 4.22% | 0.97% | 0.78% |
| Research & Development | 40.53M | 66.02M | 99.59M | 140.28M | 191.62M | 260.9M | 295.87M | 379.62M | 413.45M | 307M |
| R&D % of Revenue | 4.99% | 14.33% | 65.09% | 13.26% | 14.33% | 37.52% | 38.04% | 7.42% | 1.55% | 0.84% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.38M | 5.62M | 6.6M |
| Operating Income | -41.83M | -72.92M | -111.54M | -154.76M | -226.72M | -330.62M | -451.79M | -561.81M | -455.54M | -278.76M |
| Operating Margin % | -5.15% | -15.83% | -72.9% | -14.63% | -16.95% | -47.55% | -58.09% | -10.98% | -1.71% | -0.77% |
| Operating Income Growth % | -2.49% | -0.74% | -0.53% | -0.39% | -0.47% | -0.46% | -0.37% | -0.24% | 0.19% | 0.39% |
| EBITDA | -41.27M | -72.21M | -110.85M | -153.85M | -220.05M | -321.17M | -436.4M | -544.3M | -436.63M | -261.05M |
| EBITDA Margin % | -5.08% | -15.68% | -72.45% | -14.54% | -16.45% | -46.19% | -56.11% | -10.64% | -1.64% | -0.72% |
| EBITDA Growth % | -2.59% | -0.75% | -0.54% | -0.39% | -0.43% | -0.46% | -0.36% | -0.25% | 0.2% | 0.4% |
| D&A (Non-Cash Add-back) | 558K | 710.02K | 689.46K | 908.17K | 6.67M | 9.45M | 15.39M | 17.51M | 18.91M | 17.71M |
| EBIT | -33.57M | -68.73M | -124.28M | -130.36M | -217.03M | -417.26M | -380.03M | -547.13M | -430.08M | -307.74M |
| Net Interest Income | 7K | 118K | 826K | 3.89M | 8.84M | -106K | -3.22M | -23.26M | -27.21M | -51.14M |
| Interest Income | 13K | 123K | 923K | 4.02M | 10.06M | 1.81M | 692K | 7.43M | 16.86M | 14.36M |
| Interest Expense | 6K | 5K | 97K | 127K | 1.22M | 1.92M | 3.91M | 30.68M | 44.06M | 65.5M |
| Other Income/Expense | 8.25M | 4.19M | -12.83M | 24.27M | 8.47M | -88.55M | 67.85M | -16M | -18.6M | -94.48M |
| Pretax Income | -33.57M | -68.73M | -124.37M | -130.49M | -218.25M | -419.17M | -383.94M | -577.82M | -474.14M | -373.24M |
| Pretax Margin % | -4.14% | -14.92% | -81.29% | -12.33% | -16.32% | -60.29% | -49.36% | -11.29% | -1.78% | -1.03% |
| Income Tax | -652K | -227K | -477K | -394K | -234K | -219K | -367K | 5.38M | 7.3M | 4.84M |
| Effective Tax Rate % | 0.98% | 1% | 1% | 1% | 1% | 1% | 1% | 1.01% | 1.02% | 1.01% |
| Net Income | -32.92M | -68.5M | -123.9M | -130.1M | -218.02M | -418.95M | -383.58M | -583.19M | -481.45M | -378.08M |
| Net Margin % | -4.06% | -14.87% | -80.98% | -12.3% | -16.3% | -60.26% | -49.32% | -11.4% | -1.81% | -1.04% |
| Net Income Growth % | -2.41% | -1.08% | -0.81% | -0.05% | -0.68% | -0.92% | 0.08% | -0.52% | 0.17% | 0.21% |
| Net Income (Continuing) | -32.92M | -68.5M | -123.9M | -130.1M | -218.02M | -418.95M | -383.58M | -583.19M | -481.45M | -378.08M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.39 | -2.58 | -3.68 | -3.17 | -4.69 | -8.28 | -7.00 | -10.40 | -8.55 | -6.53 |
| EPS Growth % | -1.44% | -0.86% | -0.43% | 0.14% | -0.48% | -0.77% | 0.15% | -0.49% | 0.18% | 0.24% |
| EPS (Basic) | -1.39 | -2.58 | -3.68 | -3.17 | -4.69 | -8.28 | -7.00 | -10.40 | -8.55 | -6.53 |
| Diluted Shares Outstanding | 23.77M | 26.56M | 33.63M | 41.09M | 46.51M | 50.62M | 54.77M | 56.07M | 56.29M | 57.89M |
| Basic Shares Outstanding | 23.68M | 26.56M | 33.63M | 41.09M | 46.51M | 50.62M | 54.77M | 56.07M | 56.29M | 57.89M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 125.65M | 183.96M | 204.63M | 292.91M | 611.17M | 740.13M | 805.89M | 923.47M | 702.72M | 1.06B |
| Cash & Short-Term Investments | 119.65M | 180.33M | 195.35M | 277.86M | 598.11M | 718.79M | 682.06M | 735.46M | 399.44M | 559.54M |
| Cash Only | 119.65M | 180.33M | 195.35M | 277.86M | 598.11M | 584.52M | 446.27M | 444.77M | 392.16M | 559.54M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 134.28M | 235.8M | 290.69M | 7.28M | 0 |
| Accounts Receivable | 1.06M | 287K | 188K | 6K | 804K | 387K | 2.2M | 11.91M | 35.87M | 166.28M |
| Days Sales Outstanding | 47.84 | 22.74 | 44.85 | 0.21 | 21.94 | 20.32 | 103.24 | 84.95 | 49.09 | 166.9 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 75.41M | 130.67M | 208.93M | 295.61M |
| Days Inventory Outstanding | - | - | - | - | - | - | 7.81K | 3.93K | 1.72K | 2.44K |
| Other Current Assets | 1.12M | 1.38M | 2.19M | 2.62M | 4.61M | 6.96M | 20.99M | 13.72M | 19.9M | 11.16M |
| Total Non-Current Assets | 6.12M | 6.11M | 6.34M | 26.06M | 65.56M | 239.66M | 279.04M | 166.27M | 122.87M | 118.63M |
| Property, Plant & Equipment | 2.35M | 2.35M | 2.56M | 4.33M | 45.07M | 108.11M | 126.05M | 129.09M | 110.63M | 98.71M |
| Fixed Asset Turnover | 3.45x | 1.96x | 0.60x | 2.45x | 0.30x | 0.06x | 0.06x | 0.40x | 2.41x | 3.68x |
| Goodwill | 3.5M | 3.5M | 3.5M | 3.5M | 3.5M | 3.5M | 3.5M | 3.5M | 3.5M | 3.5M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 2.22M | 1.78M | 1.33M | 924K | 533K |
| Long-Term Investments | 0 | 0 | 0 | 17.08M | 15.54M | 124.46M | 145.91M | 30.42M | 5.69M | 13.57M |
| Other Non-Current Assets | 270K | 268K | 293K | 1.16M | 1.46M | 1.38M | 1.81M | 1.92M | 2.13M | 2.32M |
| Total Assets | 131.77M | 190.07M | 210.98M | 318.97M | 676.73M | 979.79M | 1.08B | 1.09B | 825.59M | 1.18B |
| Asset Turnover | 0.06x | 0.02x | 0.01x | 0.03x | 0.02x | 0.01x | 0.01x | 0.05x | 0.32x | 0.31x |
| Asset Growth % | 1.25% | 0.44% | 0.11% | 0.51% | 1.12% | 0.45% | 0.11% | 0% | -0.24% | 0.43% |
| Total Current Liabilities | 11.45M | 13.46M | 23.77M | 38.92M | 47.99M | 52.8M | 100.36M | 716.78M | 736.51M | 907.86M |
| Accounts Payable | 8.37M | 13.08M | 17.43M | 19.74M | 27.77M | 21.9M | 59.42M | 101.03M | 94.57M | 96.39M |
| Days Payables Outstanding | - | - | - | - | - | - | 6.16K | 3.04K | 777.49 | 794.97 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 7M | 412.98M | 421.27M | 491.54M |
| Deferred Revenue (Current) | 1000K | 94K | 0 | 1000K | 858K | 363K | 1000K | 0 | 1000K | 936K |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 13.35M | 23.38M | 24.15M | 183.49M | 203.02M | 317.77M |
| Current Ratio | 10.98x | 13.67x | 8.61x | 7.53x | 12.74x | 14.02x | 8.03x | 1.29x | 0.95x | 1.17x |
| Quick Ratio | 10.98x | 13.67x | 8.61x | 7.53x | 12.74x | 14.02x | 7.28x | 1.11x | 0.67x | 0.84x |
| Cash Conversion Cycle | - | - | - | - | - | - | 1.76K | 976.35 | 989.36 | 1.81K |
| Total Non-Current Liabilities | 0 | 0 | 0 | 0 | 31.63M | 88.28M | 100.93M | 109.61M | 234.78M | 377.34M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 97.97M | 95.4M | 223M | 365.08M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 30.72M | 85.12M | 97.97M | 95.4M | 84.62M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.83M | 7.26M |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 908K | 3.16M | -97.97M | -95.4M | -84.62M | 0 |
| Total Liabilities | 11.45M | 13.46M | 23.77M | 38.92M | 79.62M | 141.08M | 201.29M | 826.39M | 971.28M | 1.29B |
| Total Debt | 0 | 0 | 0 | 0 | 36.62M | 91.97M | 209.92M | 617.57M | 743.06M | 856.62M |
| Net Debt | -119.65M | -180.33M | -195.35M | -277.86M | -561.49M | -492.54M | -236.34M | 172.8M | 350.89M | 297.07M |
| Debt / Equity | - | - | - | - | 0.06x | 0.11x | 0.24x | 2.35x | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -6970.83x | -14584.00x | -1149.91x | -1218.56x | -185.68x | -172.38x | -115.52x | -18.31x | -10.34x | -4.26x |
| Total Equity | 120.33M | 176.61M | 187.21M | 280.05M | 597.11M | 838.71M | 883.63M | 263.35M | -145.7M | -105.71M |
| Equity Growth % | 1.63% | 0.47% | 0.06% | 0.5% | 1.13% | 0.4% | 0.05% | -0.7% | -1.55% | 0.27% |
| Book Value per Share | 5.06 | 6.65 | 5.57 | 6.82 | 12.84 | 16.57 | 16.13 | 4.70 | -2.59 | -1.83 |
| Total Shareholders' Equity | 120.33M | 176.61M | 187.21M | 280.05M | 597.11M | 838.71M | 883.63M | 263.35M | -145.7M | -105.71M |
| Common Stock | 3.37M | 4.35M | 4.97M | 5.66M | 6.44M | 7.22M | 7.65M | 7.67M | 7.75M | 8.15M |
| Retained Earnings | 111.28M | -139.31M | -263.21M | -393.31M | -611.32M | -1.03B | -1.24B | -1.86B | -2.28B | -2.56B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | -21K | -149K | -146K | -113K |
| Accumulated OCI | 5.68M | 13M | 22.78M | 42.45M | 79.9M | 133.02M | 3.78M | 3.45M | 721K | 1.78M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -43.47M | -60.18M | -95.1M | -138.8M | -175.94M | -271.55M | -417.65M | -495.7M | -467.36M | -306.2M |
| Operating CF Margin % | -5.35% | -13.07% | -62.16% | -13.12% | -13.15% | -39.05% | -53.7% | -9.69% | -1.75% | -0.84% |
| Operating CF Growth % | -1.36% | -0.38% | -0.58% | -0.46% | -0.27% | -0.54% | -0.54% | -0.19% | 0.06% | 0.34% |
| Net Income | -32.92M | -68.5M | -123.9M | -130.1M | -218.02M | -418.95M | -383.58M | -583.19M | -481.45M | -378.08M |
| Depreciation & Amortization | 558K | 677K | 734K | 880K | 6.69M | 9.45M | 15.39M | 17.96M | 18.91M | 17.71M |
| Stock-Based Compensation | 1.71M | 7.32M | 9.71M | 19.65M | 37.49M | 53.17M | 66.83M | 64.18M | 66.66M | 95.51M |
| Deferred Taxes | -652K | -227K | -477K | -394K | -234K | -219K | -367K | 5.38M | 0 | 4.84M |
| Other Non-Cash Items | -7.5M | -3.51M | 13.81M | -30.55M | -5.93M | 85.97M | -68.2M | 12.45M | 24.77M | 60.98M |
| Working Capital Changes | -4.66M | 4.07M | 5.02M | 1.71M | 4.07M | -964K | -47.72M | -12.47M | -96.26M | -107.16M |
| Change in Receivables | 228K | 777K | 99K | 182K | -1.87M | -2M | -6.66M | -11.53M | -32.77M | -118.61M |
| Change in Inventory | -3.33M | 1.55M | -5.71M | 0 | -5.64M | 0 | -75.41M | -55.27M | -78.26M | -86.68M |
| Change in Payables | 3.4M | 4.71M | 10.76M | 8.26M | 7.51M | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | -1.04M | -672K | -941K | -2.65M | -5.16M | -291.2M | -110.58M | 61.73M | 286.47M | 6.88M |
| Capital Expenditures | -1.04M | -672K | -941K | -2.65M | -5.16M | -19.86M | -23.7M | -14.49M | -2.44M | -1.43M |
| CapEx % of Revenue | 0.13% | 0.15% | 0.62% | 0.25% | 0.39% | 2.86% | 3.05% | 0.28% | 0.01% | 0% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 3.36M | -530K | 9.54M | 288.92M | 950K |
| Cash from Financing | 105.74M | 117.46M | 124.72M | 203.27M | 493.59M | 602.65M | 351.39M | 396.77M | 134.29M | 443.93M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | -8.4M | -8.5M | -8.39M | -13.12M | 17.38M | 26.88M | 11.54M | 5.15M | 10.29M | 11.22M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -44.51M | -60.85M | -96.04M | -141.45M | -181.09M | -293.1M | -441.88M | -510.19M | -469.8M | -307.62M |
| FCF Margin % | -5.48% | -13.21% | -62.77% | -13.37% | -13.54% | -42.15% | -56.81% | -9.97% | -1.76% | -0.85% |
| FCF Growth % | -1.37% | -0.37% | -0.58% | -0.47% | -0.28% | -0.62% | -0.51% | -0.15% | 0.08% | 0.35% |
| FCF per Share | -1.87 | -2.29 | -2.86 | -3.44 | -3.89 | -5.79 | -8.07 | -9.10 | -8.35 | -5.31 |
| FCF Conversion (FCF/Net Income) | 1.32x | 0.88x | 0.77x | 1.07x | 0.81x | 0.65x | 1.09x | 0.85x | 0.97x | 0.81x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15.67M | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -39.63% | -46.14% | -68.11% | -55.68% | -49.71% | -58.36% | -44.54% | -101.69% | -818.43% | - |
| Return on Invested Capital (ROIC) | -4613.05% | - | - | -5304.74% | -899.32% | -129.89% | -68.22% | -77.78% | -106.54% | -105.44% |
| Gross Margin | 100% | 100% | 100% | 100% | 100% | 100% | 54.71% | 76.28% | 83.36% | 87.83% |
| Net Margin | -405.54% | -1487.3% | -8097.84% | -1229.53% | -1630.03% | -6025.53% | -4931.56% | -1139.63% | -180.51% | -103.97% |
| Debt / Equity | - | - | - | - | 0.06x | 0.11x | 0.24x | 2.35x | - | - |
| Interest Coverage | -6970.83x | -14584.00x | -1149.91x | -1218.56x | -185.68x | -172.38x | -115.52x | -18.31x | -10.34x | -4.26x |
| FCF Conversion | 1.32x | 0.88x | 0.77x | 1.07x | 0.81x | 0.65x | 1.09x | 0.85x | 0.97x | 0.81x |
| Revenue Growth | -41.94% | -43.26% | -66.78% | 591.57% | 26.41% | -48.02% | 11.87% | 557.93% | 421.2% | 36.34% |
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| North America | - | 10.58M | 2.65M | 2.68M | 6.86M | 44.16M | 191.68M | 233.22M |
| North America Growth | - | - | -74.94% | 1.02% | 155.92% | 544.05% | 334.09% | 21.67% |
| Europe | - | - | - | - | - | 552K | 869K | 123.34M |
| Europe Growth | - | - | - | - | - | - | 57.43% | 14092.87% |
| Asia | - | - | - | - | - | - | 74.17M | - |
| Asia Growth | - | - | - | - | - | - | - | - |
| CHINA | - | - | 10.72M | 4.27M | 922K | 6.47M | - | - |
| CHINA Growth | - | - | - | -60.14% | -78.43% | 601.30% | - | - |
| UNITED STATES | 1.53M | - | - | - | - | - | - | - |
| UNITED STATES Growth | - | - | - | - | - | - | - | - |
Ascendis Pharma A/S (ASND) reported $646.5M in revenue for fiscal year 2024. This represents a 4049% increase from $15.6M in 2012.
Ascendis Pharma A/S (ASND) grew revenue by 36.3% over the past year. This is strong growth.
Ascendis Pharma A/S (ASND) reported a net loss of $232.9M for fiscal year 2024.
Ascendis Pharma A/S (ASND) had negative free cash flow of $112.2M in fiscal year 2024, likely due to heavy capital investments.